<SEC-DOCUMENT>0001144204-13-052060.txt : 20130924
<SEC-HEADER>0001144204-13-052060.hdr.sgml : 20130924
<ACCEPTANCE-DATETIME>20130924090528
ACCESSION NUMBER:		0001144204-13-052060
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20130924
DATE AS OF CHANGE:		20130924
EFFECTIVENESS DATE:		20130924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		131111196

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>v355333_defa14a.htm
<DESCRIPTION>SCHEDULE 14A
<TEXT>
<HTML>

     <HEAD>

          <TITLE></TITLE>

     </HEAD>

<BODY>

<DIV style="text-align: center; min-width: 708">


<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">UNITED STATES<BR> SECURITIES AND EXCHANGE COMMISSION<BR> Washington, D.C. 20549 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCHEDULE 14A<BR>(RULE 14a-101)<BR> INFORMATION REQUIRED IN PROXY STATEMENT </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCHEDULE 14A INFORMATION </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proxy Statement Pursuant to Section 14(a) of the<BR> Securities Exchange Act of 1934 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 180px; text-align: left">Filed by the Registrant</TD>

          <TD STYLE="text-align: left"><FONT STYLE="font-family: wingdings">x</font> </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 180px; text-align: left">Filed by a Party other than the Registrant</TD>

          <TD STYLE="text-align: left"><FONT STYLE="font-family: wingdings">o</font> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Check the appropriate box: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Preliminary Proxy Statement </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Definitive Proxy Statement </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">x</font></TD>

          <TD STYLE="text-align: left">Definitive Additional Materials </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Soliciting Material under &sect;240.14a-12 </TD>

</TR>

</TABLE>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SYNTHETIC BIOLOGICS, INC. </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Name of Registrant as Specified In Its Charter) </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 252px; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payment of Filing Fee (Check the appropriate box): </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">x</font></TD>

          <TD STYLE="text-align: left">No fee required. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Title of each class of securities to which transaction applies:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Aggregate number of securities to which transaction applies:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Proposed maximum aggregate value of transaction:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Total fee paid:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Fee paid previously with preliminary materials.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Amount Previously Paid:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Form, Schedule or Registration Statement No.:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Filing Party:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Date Filed:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="logo_synthetic-bio.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">September 24, 2013</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dear Fellow Shareholders,</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Over the past year, we continued our efforts to develop novel therapeutics that address specific unmet medical needs. The programs within our pipeline have progressively matured, and with leadership from a seasoned management team, strategic collaborations and aggressive research efforts, we have positioned our Company to reach several key milestones in 2014, including the potential to have three programs in the clinic. Our progress this year further validates that we are on track to meet our goals and emerge as a player in the area of targeted biologics for the prevention and treatment of infectious diseases.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The investigator-initiated Phase II clinical trial evaluating <I>Trimesta</I><sup>TM</sup>, our legacy oral estriol candidate for multiple sclerosis (MS), is scheduled to be completed in January 2014, with topline results available shortly thereafter. The principal investigator for the trial is Rhonda Voskuhl, MD, Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at the UCLA School of Medicine. Throughout her career, Dr. Voskuhl has conducted research related to the anticipated therapeutic benefit of oral estriol for MS patients, based on the
reduction of relapse rates observed in women during the third trimester of pregnancy, the period of time during which estriol is naturally produced by the placenta.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Trimesta&#146;s</I> continued appeal was highlighted during a successful investor day this past June in New York, which attracted a number of investors and key media personnel. Dr. Voskuhl delivered a keynote presentation focusing on MS awareness and the potential of oral estriol&#146;s effect on the disease, as well as the current unmet need in the market. We anticipate this study should generate positive results, and we believe <I>Trimesta</I> will eventually reach impactful commercial success as a collaborative treatment to address the debilitating effects of MS.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Going forward into next year, the primary focus of our portfolio will be directed toward our anti-infective biologic candidates. Our lead infectious disease candidate, SYN-004, is a novel point-of-care oral enzyme prevention for <I>C. difficile</I> (<I>C. diff</I>). <I>C. diff</I> bacterium is the leading cause of hospital-acquired infections, and in the U.S. alone infects 1.1 million patients, with 30,000 associated deaths each year. Patients treated with IV antibiotics are highly susceptible to acquiring <I>C. diff</I>. If they contract <I>C. diff</I>, these patients can spend an additional 4-7 days in the hospital, costing
the U.S. healthcare system in excess of $8 billion annually.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SYN-004 is designed to be co-administered with certain IV beta-lactam antibiotics and to neutralize the antibiotics in the gastrointestinal tract, therefore protecting the balance of the microbiome. Roughly 14.4 million patients are administered &#147;SYN-004 target&#148; IV beta-lactam antibiotics annually, representing an estimated target market for SYN-004 of 117.6 million beta-lactam doses purchased by U.S. hospitals. While the final dosing regimen for SYN-004 is yet to be determined, the addressable market is extremely significant. Currently there are no approved treatments designed to protect the microbiome from the
damaging effects of IV antibiotics. This worldwide opportunity could represent a potential multi-billion dollar market.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our other two infectious disease programs are being developed through an ongoing collaboration with Intrexon Corporation (NYSE: XON), a synthetic biology company led by healthcare visionary R.J. Kirk. The first monoclonal antibody (mAb) is intended to neutralize the <I>Pertussis</I> toxin. The incidence of <I>Pertussis</I>, or whooping cough, increased to 41,000 cases in the U.S. during 2012, and there are approximately 50 million cases worldwide, including 300,000 deaths. To address this growing unmet medical need, we have identified two synergistic mAb candidates designed to target the <I>Pertussis</I> toxin. Our mAb
candidates are expected to enter an IND-enabling large animal study before year-end and, if successful, into a clinical trial thereafter.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our discovery stage mAb therapy for the treatment of <I>Acinetobacter baumannii</I> infections is also being developed in collaboration with Intrexon. This is an incredibly difficult to treat pathogen due to its rapid and well-established resistance to most antibiotics, producing mortality rates up to 43%. More recently, deadly </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">forms of the bacteria have shown up on the military battlefield and in trauma centers. As the urgency to develop a treatment remains very high, we are continuing the development process to seek an effective mAb to combat these deadly bacteria.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are thrilled to collaborate with Intrexon, and believe that the recent success of their IPO reflects not only their innovative approach and prominence as a thought leader in the field of synthetic biologics, but also the potential of synthetic biology as a whole.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Looking to the future, we believe we are well-positioned for long-term growth as we actively pursue additional candidates to complement our growing pipeline of anti-infective biologics. We remain committed to advancing our current pipeline and we believe this strategy is an effective way to continue to add value to our business.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On behalf of our team, board directors, clinical investigators, patients and their families, thank you for your continued support.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sincerely, </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="sig_jriley.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jeffrey Riley<BR>Chief Executive Officer</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>This letter includes forward-looking statements on Synthetic Biologics&#146; current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as&#147;may,"&#147;should,"&#147;potential,"&#147;continue,"&#147;expects,"&#147;anticipates,"&#147;intends,"&#147;plans,"&#147;believes,&#147; and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our ability to reach our milestones, the
expected results of the Trimesta clinical trial and the market for our product candidates. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics&#146; forward-looking statements include, among others, a failure of Synthetic Biologics&#146; product candidates to be demonstrably safe and effective or successfully commercialized, the development of competitive products, a failure to initiate animal trials or clinical trials and if initiated a failure to initiate them when planned or achieve the desired results, a failure to obtain regulatory approval for the Company's products or to comply with ongoing regulatory requirements and other factors described in Synthetic Biologics&#146; report on Form 10-K for the year ended December 31, 2012, and
any other filings with the SEC. The information in this letter is provided only as of the date written, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this letter on account of new information, future events, or otherwise, except as required by law.</I></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">



</DIV>

</B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B>

</I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA`0`!`(```````/___R'Y!```````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_synthetic-bio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_synthetic-bio.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```&_```&<(``"`U```FU/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`+P#^`P$1
M``(1`0,1`?_$`0T```("`P$!`0`````````````(!PD%!@H$`P$!`0$!``(#
M`0$````````````!`@4'!`8(`PD0``$$`@$#`0<"!P````````4#!`8'``(!
M$#<(0#`1$A,4%A=0%2`Q(S48*#@1``$$``4"`@8$"`<1``````,!`@0%$1(3
M%`8`%2$B$#$C)+8'03*%%E%Q-;5VAL:'0E*RI=4F-B!`\&&!H4.#-(2T)96F
MUD>W$@`!`@,%`P@'"0`````````!$0(A$@,`,4%1!$`B$_!A<8&1H3(%$"!0
MT4)B(['!X5*2LC,4%1,!``("`@$$`0('`0```````0`1(3$005$@87&!\#!`
M4)&AL<'1\>'_V@`,`P$``A$#$0```;F[-4LUWH#ND_6YGZ/]#8WB?5?1,@D-
M59ZGC,,7=YM-.I#ITG8O-+N;B88"WW-BFQ4R':S!XS0B>R5HBFL,-!#C7+DX
MW]P-#\CE%$YWWAT>`Z]V;\?%K\JH_49^&YEHLW.BG%Y^M1Q8C6KBLU.K`2ZM
M:-Q,R,/%IF;0GN7%9M">H^T719JIUD.$S//#;WSW.`&H;Y&I7UKZAN9]B^3:
M@M0*RZZ9\7F8W.K'%YL-QB(7>KBLU.K`F.6'+$ZIK8GN5Q(H3W+BLVG74UL>
MF*V*Z=O7?%17XI\5F^_>1G_O#?K\BQ5S'`<]O3O]0NE+L;^=&E?IX:C5*XP\
M+Q360G5-!"\5/<::8<V4\1&U:T>P92(<J8XA"LQ"\4T$3>8/P_R4[IKBETZ[
M\'3_`#/%A[^FOQ>SOK??]IG2_P!!U?V24K[16Q5D\*G2766^YJ=5,43&5X5[
M"P.*V*S!8?"=4XL+N(MJ6XYJOU4U9T"YH?AA$^QEE`````````````````/_
MV@`(`0$``04",R?EHY;-Y&4V7A4IU7WYLD)J+LL>LX25272Z7?9[NN@D?TOR
M?-XO<DVC3M_,[7K>9&[0CXBO:^)6?9<S#VO888G%Y(,EX%A,[0*NWY&\!303
M(K@/X6D5P`,\;S)@Y!_)R12`!DMF<P;5@P(W@5:?[`8X<7PT;L)G:!5VR(W`
M*`4!.CBTHG-X3:;&RNU^P]H$\@Y&2K\5Q\U9-/1'3H<C8J0(HN#E;%0Y9H<&
MY?M:GI\,`V'959N`5XQ0V6OV"LYG$>3!/8/2U;_CV,Q&,NY@=HJPU(!)J![M
MW]VD\3<\LL@5SRBN@]A6E(+*R:=I(A?<PA<=BODA.#DHL3M_0/=N_NTD9_LO
MBN"'O#9%@T*C_P``U)A!O]O$@IEH0;]301@=9UI.2,6L3/)-[.(^8KZ]HB1B
ML\)10O)H8P=BH?7?<#*![M^1M:;BB=`]V[^[2>)N>66>+?;_`,LLFG:2L;[A
M\+@_^4E?Y8G;^@>[=_=I*;BWWH^K*;N*MF<^\D8^;B@:).R47D8?8V*>I$`[
MD38#-7$%T'262241T,+X;%7YYBZ^N928C#VS0IXTUJ0<1*EJ]AZBAD.B3'4C
M6`HAD*@=-MBQ@.,D`QA655P%V?`"90)B<`B4&R>1&!2-I#HS%8L'ED`B4YPY
M655I1UO15..V_P"`:DPOR$>)@*AKN+ECX`3*!,(A571XQ+JJ@LVW8>,E<,W:
M;BMUHKA`:P*MCE:.D,61EH!5:Q2NK597:2.JFJ7XB>>0;Y$;(O'+11*O<DW_
M`$WEW_N'XK@ZD%*VYE_=I(G/XE.>ET\1U"6T2W;H[Y?7`U`[XV?)^S\FG=O+
M8;GG==5X_K)6>Y<[-N^K.*O6Z$=ZK+O=,15<[^L__]H`"`$"``$%`NA".R/Z
MQCM-&+[9IM[OY>O35W3Y_IN]%--D]_9\YQ[4D02%L1L@$EM>O&V^N?NRZR_L
M^<XZ<>S)L]G[(L`=#51,V;K\)*I+Z8V'.WNY08^$DM>?BU]2NW1<IDH<@KG`
M4R.WT<G>=`I\*_2D!CCW?K/_V@`(`0,``04"Z-)"(^F4^TWZ:PE;37GCG7GU
MS9XNUYV2;%D%DMT%?5>[GC^!JZ5:*R",(.0?J5D_FIIN-M>?BXZN33`5Q&)-
M')7$7"/T[CU.^FJG'*"J><K*:9R^T]Q5B3^IB(3;X/UG_]H`"`$"`@8_`O0^
MKY7K?H5-XSO>UTUQ_C$I$`D&H$:B-4TJ&N:VOY=/38YX+2C7.:"\>&JK1>7@
MB]Q41LM(S"R&_;]VRW5>5_OL6.O&U/U]</=2IHH;$Q(&)&>=UF_U*S>*[X#N
MO5%(E-Z8EJM@4)3U-PH;,T^I16JTG-RWW=7?S;4[2-,I?+'H<">X6<7MW5/1
MTM.(_;CC:3S8"C4`\39BTQNEBYL$S!C=`6%6@YKZ1Q!4=H]#:5)CDJ*AB`@@
M3-S<V,+TL[0UE=J(.!;-O+&9JA3BOS`C"P=$*-JX5=H<SGY0/.(V-70E'Y'K
MQ[+XYOLY]'B,(;>U1"^]L$Z^FW!-:K),OCC^I9DYE3%%LS3:*N)F,8)7[K\@
M(H''`R3!>D6?Y=1#@]4<3"'RXQSN2Y05]M?_V@`(`0,"!C\"]#*6NT=+B,$H
MEIM<);_C=-B5B5*N538FF#0U1F-Y;G",U,`Y`C`!+K<2@148F'*/;U60W[>M
M,[N6%N+21NI')#F,C^(L:53Q#;Q5IYQ$4=S%$AWY$&W^UY?.G#;6:UR;M(MF
M<V^]#,2KO`&MB27;26#'WV%"O!V!S]1VIK5*<]`M5NZ\S&+6EA59DN<$(4G=
M6U/SS3\*AY46FD^G4-,"B09#2>AE`.[("DU-[#*)DL_3S,?(\MF:5:Y"BM.+
M3>#B-JE>%%OH%6_E/W'[+;['CO';;Q'OM5U=>@]Q>][W&G%@"JYT)BUL83I#
MHM3\TK.9P2U6-$<QO8!,KYKY2TCVU__:``@!`0$&/P)L&L&*5*:_`[B9G!&O
MC[%,CQYBM_AKCE9AAZ\<J%)8RF(W*-VW*D4;47S>;1TAN>Q7>;!CUP_R=&)"
MY/,:V0]#%4EM/$1YLC!*Y^WC9"8#$U$7!,&HC?4G1E:X-W'CQV""A0CF9W8"
M1A/=70[B05KO*YSD=]+EQ^MT^'>P3\>D-.X"/._=0D<A`@1DB2T("PBZI'8Z
MPF#8UF+GHOAT,P2,,$S&%$43VD$41&HYA!O:JM>Q[5Q14\%3TP@5$?->\BWP
M:Z:5HR1*L<%L7=S7A?FW,QN^'MQN:HLV+B8HS2+-ON/7G*["+W*1'DEC\P%3
MQQSL@9A@`KR7%<..%@YC%:T0FA:BY6X88)/HN5VW)9]1*[C5W0)$HB<KI321
MI!/.I;2Q1\Z!<5#A9A`*_;ZB.16L>[5:6!:<KN)MEQ^8S7A3[VQNJ2P"8###
MU8TB5E/#GP9+7)B@I`D>B^R,WRC^88_?8,V'%+5P$EPA2YMA-\@ZESVG.%DR
M&9'I+:-3/CM`9<K]-4Z#5MYQRL4<IG6]^:-R6=6,AT[9@4L7U\8+UBA,Y931
M1@B`HF$>WRM$URMAV8^77U@L,R$6#<6]E9UDMF"L)'F0I,MPRA*-RIX92,^L
MQS7HUR5O(Z=QG5]F%Q`I($H)`GB,2-)CG&JN1#1907C=E5PU5N+'.;@Y10*O
ME?/;*<?/H0H%[R&9+-I#>8FE&CRB&)IA&YRX)X-15Z+/M)WS6K8(,FO-GR>7
M0X@=4C`CU9,AXPCU#$:U,5\7*B='[%>_,FZVNENNTV?*+';:^IHZ^S,;1UM%
M^7-AFRKAZN@=]O?F32[K5VO=K/E%=N=#3UM#>&#K:.LS-EQRYDQ]?5K+N[6R
MN)0^5SHXY-I.E6$AD=M11D:!AI92D:%I"N<C<<,7+^'KA/8KVXI=U]Y-UVFS
MFUVYT.P:.OLS!UM'6?ES8Y<RX>OKY13X_*^2@G67W^[C-#>V@I<_9\AC!B;V
M2R4AI6U"N4>=5R-\$Z%/JYWS6LH)\^A-@2>73(AM(CPDTI,=Y`DTS#<U<%\'
M(J=?^XO^]>CRY9_FY%BQ0DD29,@G,@QX\<+%(8YS$5HQ!$-JN<YRHC43H4"K
MY7SVRG'SZ$*!>\AF2S:0WF)I1H\HAB:81N<N">#45>N<3^0SOF36A!QJ#L)M
MS)Y1#&&P+S7B(?=),UXVCF$@D.WR+G42O3ZN;KD<GE7*;ZPIJGA%O<26VEI:
MVL>*R!84Q#3&1"%E*XP8JDPR,4F"JB>OK9<4EW%#4/F`!2U5,\@+N<;,6.`D
MN77>_'F3W2?]D$18[5R-1"/9JOK^16]CSV'!7;SAR95U.LHD?`D10,NX2S9H
M8&J:2-FWL!LU7*HU8N#FIS1TGMH>8\>K:@]7/'$*K)T.;:5E#/L9$-4=7CLJ
M^1/87ZS0%(=N$?3$]'2)!5<0O@N=ZYG*XRO5[U<[%RO7#U_XUZ:,;48QB8-:
MG^'BJ_Y_3I3P>T\B-EA0;)C&,5RZ2&>,F8+M1V+'(YGFQPQP5$C'618T!LV6
M(CE4+HVHI'2:=A'9(<X)#*XL?'*178+ZQDZB6L!7K%F,5[-5FF5CF/<(HB-\
M4SA,-S5P56JJ>"JF"^BCE\<T9-AQ\T]%J2$#&?/CVRU[2$CS))@Q1FA+!1V0
MBM0@W.P=F:UA.S`FV58.(:*21QJ^A.?'$S.Z?M]A9"255!L$F*\NV6.0J$1V
M;'*Y!D^9'RVX=*-/F-9.Y/#IH\DT6(D84>,^57V,6UG6&V<)$>YLI')'\&"<
MYB->SFE.4)[#CM:2Q">'L21[GCA=*7)S3E>-2!KXN>7&5I'M5%*U@W.,CD'0
M+,-V85D>X;7HJ-CK9R(L>$281&HBF,V+%:QF=7:2*[)EU'YO?Q9.37FC)O\`
M++W00;=TGMU<'3:V.W8QY*ZJMU,TAY,"/&@\`<?@.PG3(=P:$S`:[B76TUA:
M1H68QXP1;\T)`ZCGHT6?.N.&"RN+<C=VZDN)BQIZVA)<3[NW<-IP,,2.]%#%
MW1D;&F:C!JS*-Y"-8!47B?V[\-7/7+/L+XEINN??JM^T?7`?UI_9SJ324D"A
ME195D:T(2TBV!I"2#18<1S&.B6D(:!0<)N"957%5\?P5'?8=/%[+O]KVF/-!
MG[CLM;7WEA.S9=BS+ER^M<<?H^2O[Q_B6+U7\9JZWC1X-;N]`L^':%ENWDZ3
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M2>01IFTJY36[=[MMN@/`-C!QFXSWE*N08V"ZH;NDY!?55!-K>UD'3VMO!CCN
M(DJ7+<^8V(X,)AIT*6W17,I2)&)X8#Z#Q;YIJ:5(BA<.197%;W^LNX\:4$U:
MV8"/%E2G6045$Q*`B/VVL\VJ_#J?8\,J)E'22M,K8$QT=,DM[<TQ\6'%4H:V
M&XR^2.A3-;ABU6,5H1<4JYXM"=6\:HH$T&<9=&7#JXL>2+4"\@2:9AJF+7*U
M?H7K@WZ8\9_/4+T<3^W?AJYZ=SRFC&?67!OZPC!&CMBU-GA'"&:J@R$0-X15
M4CWL7"9BKBJZ0-B<3^W?AJYZY9]A?$M-US[]5OVCZX#^M/[.=7'Z8V'YEX_U
MP']:?V<Z^2O[Q_B6+U2<9M*WDIYU;W+7+`AU98CMY;SYX])\BXBF7`,IJ+BQ
M/-C^/K\C\Q_Z?2_^0=<Y_0[DWYEF]<3^W?AJYZY9]A?$M-US?C*&T#67`IVT
M*I-(;;"'R+C,^NW+]O*<D-9T4:&RL5^EFR^;!>GV%A5&*/1DT-]7D8^/9Q([
MID8DK;B,X*#LH4J"WV1L$=E<-5&KM1EQ2<;IKC?74.14F-=AA1XD6OGQS1II
MQI`M)ACS$"_*)JY&(YV=RKDTW\OY66-,;5<=AP&1Y[-,<0MW.OJ2$D!^HUSY
M.6JG'*Y!8*)VDKU1'M:^17C>()CK&8DDC,ZA"V=$DR<N'F<JCC>#<41SD3%4
M]:=NMXSP%17#CR_.Z)/T\F+XQW-1"8L(U5^E%7!R-=Y>G#N6M@O:W,V0%AS`
M,N=?)HL88P7(Q4^EZ.P7Q;X(K3QC"D!?CD,`C"B?E<K'92#5S797-5/Q^BX)
M:634;""V/,AU\W)<(6PCD=$BQVQ9`)L6=,"US@N1PE:UJDSM:Q7M5].^ZL[=
M]@>;!E"#(6^E'$5\Q+%1Q#S9+)^`]9ZL*16.15SKAFZAS=O*A[R+'E;2<+;S
M8NX$PNWF`S/T90,V4C,5RN14Z;`YC.XT"#98Y(7)I-6*)/V9`&=EC6CT#*VI
ME$[U+D=E7\'3#1$OJ,;0M&L2KM6ECD>CR.60]UW$N)6LY'HU<I$'@U/+CBJQ
MI<*F[C:Q?$=O=E[C+0B2VS`21QU:.JB3(CQL01@1Q%:UOUL5<KH](:UK17,L
M*R(E22=%99RH[4.YQX\!Q4E&"U(I/,UJI[-W\5>H-I`XSH3JV9&GPC]ZY"71
MEPS,D1BZ9K8@2:9AHN#FJU?I3T,O>"CIYEK39O>JGE,^[V/<(TJ'[</>9T=N
MYCN*UNHSQP56^*>$RFN88;"LL`J"7$.BY",Q1S51S5:01A$:CQD8K2#(U'-5
M'(B]"Y;'K8?'S56?);S[^U9$B;X;ZUVJZTMGP4UVS-),Z?6>F'FPZET5[$WU
M5.T-U%UY,;5VTD,P/MH9H\AF21'8[RO3'#!?#J?]UJGM?=-KOO?K*;K[+<[;
M\HS)>GI[LGU,N.;QQP3J+/YZ"&L&DUM";/N)E-$A=R)#"35DQ["`'WDP`M34
M5?-@C?7XI&X=&#'IK$W>!NCV$JSCRWRXL8;9@)<N7,4@3Q8XLN1^FJ>*>OJ!
M]Z:GNG:]UL??K*%H;W;;G\G3(FIJ;0?U\V&7PPQ7JJA<@K8</CG%=]VY\^_M
M:^)6]\G"++U9[[8#G[R<K,-8CL'*C688X=`EQ.-!E1901R(TF/R+D1H\B.9B
M$"<!AW3AE"4;D<US55'(O7]D_P"?>2_TSTO&[B3#_K+#LH`ZLTUL67;1-HYM
MH*$-A@S#:,,V)%#YA-7-BGKZB7M%Q[8VL'7VLKNUY)TMS&-#-[&992([\\>0
M]OF8N&.*>/4NBO8F^JIVANHNO)C:NVDAF!]M#-'D,R2(['>5Z8X8+X=6LG@X
M:UMS""^GN6PN0S;>1`864TCX<^)(M)R0C.E5G\-C28B<G\;HLF\HP]S($PTN
M(#R5]FCR1PQAR#&C.8.Q-#''9H;MD@8\N&7*KD44F0?DMJ$>?/`GV<4<0^<;
MV-U7U=;6SDTG.SID,SS-3'%N*+(&$_""\(B&2/+&,E"_BL60Z4"6T$AK56I"
M9TZ4,F5V"ZI&N^LY/0Z)8Q`S([L?9F8CLCE8\>J)WUP&:PBY7L5'MQ\%Z)(X
MS,U6)F?V>R?]'M7Z4"P];?!&"$,WE3Q<\O4@CZ?D58^.%5F3:\<@L,47*V01
M[[.O<X#XXV-1Q,'*C5;X^+>ECIR.T5B%61Y32DDJ33R9$F*C9.DJ?Z/4TLWC
MACX]7%E'AEDSBOG75B*,`NE$$8SSRI.5''(R''*;Q<Y<&HJ8N_#6<]N9,&3'
M&U9E-7@<&<JS<QX[9-BY1DCQR5RMU!#$Y2CD95<HGA4;NOEA-D,XT0(?OKG9
MR^NL+7CJZD&E$WN$"KC3)Q\'/]ED&[*?(Y<&HJ]%`KYDB/'Y+=!@33%EOK;"
M(S;>^\?#-@5\B'3ED:GLW-5VZ0SG97N<(?7R[_0Z;_PG.?1R_MF\W&SAZFQU
MM;M_=8'=L^AY]GVK6W&/DV^?/Y,>N'3OE1'LH$(/%+$G-86)(,$$,=:ROK8Y
MP2CZ]A9#LR1][IND`*9`G:YY$.7T<L^POB6FZG_=:V[IVO:[[W&RA:&]W.V_
M*,.)J:FT)]3-AE\<,4]'RHM.9QM3A\"9RQ+8YH4Z;7LEDK:^131I@X(3N-N9
MT+%`JUS3,&_,UPT)USPG&@60OEO+OHTCAA+,;&/E2&QRQ.0GAN*B69JUIXH!
M@<?%=,>5WMVR/1\M[2]C0R4D#[[(0]Q"M)O'V79*:'(XS&NAU`3RS0Y-O"8K
MPM:Y3!&3%KF(_KDVVV>W^_MSH=N[AV_1[71:6Q[M_P`UV>3#3W/O&3#4\^/H
M^2O[Q_AJ+Z.5Q.-`-*MI5;MV1HXPFD2()I`!W(`!,CM4Q:9QVM:Q%,Y5]E[3
M+UP"%\MJODJR(O&K=O(K5IRP0I&+#-(:'F$18)V74QEJY,2B)'B"D$CM&0S&
M!$+KE`);K(<71KI$DM16,N)P8\.YKIACLKR3ZP90@&!7F<XXT$%'$\<N"_-.
MK&?ATJJL>'</%+Y&&JY6G%ZB773H_&8K)L(O&AVKN2VC)K[`<@87-WXM;!4U
M-+T^Q@:_^]"'_*3KVT30_P!>,G\E/[\__]H`"`$!`P$_(6B`,,@3<C-'*7!1
MO!D@BSL2JF%MQB(<);2M:XIE,PA!JU!"BUD25)2%VE7.;R(C!(#ZF`'[^LHL
MYQ&-_,L<**J5,-C+[&,,"<<1-HP.(]\UYD)SF'\D]=5,\!59<6TL0"!4HBLD
MS:(T$NR##926Y1#SOBBV"3]I7-G"]$;>Z>3WE_R5=`/NF!9[6]YZNP'U3*$_
M"E!.@]XUJ_"E!.@]HU+%#1<5P09!=5J_P)81H/:-:_,??0S*W/YI,3WM[SU=
M@/NF1.,^`GZK#*&*5`GO+_DJZ`?=,"RC;H;CU:+=O!!WZK`B28FC;BA4VS>C
MN)J<25>6?[>HT*V(Q*JYKC'W8T`YF0Q-F1:\'G:W)=SKOD`-N6U#:MJ;<\IQ
MXT[)T!!E@`8E^TTJNQH2K*89=<U4/M!IW9?27^L21_[.=B,TZPY+8=C>8[/)
MAI*LI^"QQ1$O6>HV6:S'])Z4TLZ-.LF"E<$\EITSM3OZ#W9K1T>$#ALO4<*/
MVKT\;.,,[L`JEJ)8--V!"/R9H-GM7M#@?\*IS#?[3P&VTR`K2F'@B<EAA]!<
M8;+XGV5N7BUZ3,OE7]FO<!ZV#3P,60GGL3^&]BL6$CI0!Y.^PJN#T4NJ*[-"
M/5N+$A!H^(/+\@OB(3B/D!5:`IB<)2D(A48E=-Q3/C[CQBP"N;**KX5_)J7`
M>MH4^@N-64`XNMV+##]"@!AG>&Y_QNGL/_M/`+*7HAEQAO%%?&NV[GF*T&>)
M9L"T[H#'*%I7IT9P1P5;C8VCC,_C<>$.5G2L*%DER4OP2'UD-5TK_(DN`?$G
M,0<0\K9+!>43\4I*13@)LX:'#F>?YQU"T,US+IP2LQ[S_P!GR=+S0(:GD#O$
M?':U?8FT(#AK$H(PPV+EROJKW=%0U^HQW.MV(4RI4RZ/@W]@O<!ZTA9Q^;"!
M'=ZA%A+(`*CME(2?3SBUO.JWMH)_WX"=F)!1(_E0^K_UQ!_8CO-=U!X%D&$4
MBA6&8Z"'DOY4/J_]\0>,&RY/WSSX`-`3]5AE#%(H\#=W`;`&("]"L,?\V`A9
MJ04`G_?@)V8D%$C0DA%"$65!&N!&2`*DC8)`&N5^)4EY57>7`F1K%9H0]ADM
M5898NGX0ZRK:0DP[:*K1TN\.+9`S(Z2JX3)!#,H)Q%&R)HU4-F![56C1SR!G
M.-&#J-?DG^A&=P8GAQB!1?VXZHD:6140"O49]_TT19+[<0-H&'6EQ9ER%6(W
MY4/J_P#?$$P-@J$LJY8,FBIOHH(4Q\02H2AX`$W-#N#@7IT\1%@GU^BW7X8I
M8("Y&DQ&Y-I/%UJL%M3!)*@BMD3#J4OZ`R?$H$>;?1?MJ.U0\_V;0_:\?XM^
M\__:``@!`@,!/R$)B.1C&CTL,<LF!:D/-:WI3@YU@4)-257X?.#-_2OM$5H'
M(3$J8E3!*XQ,3$Q&$[F)B8F)B,J8E1]%B6/'432!W[^/,\=/YG*G#,,J'#PQ
MU#?)4JIW*E<.H;X>+8$D*$Z5`8;-B@L]Z+8(.Y5_:A/1>VL;*_LB-=6,-6BG
ML/NHI@N\#"$KQZ74&.H;Y'AW$E<.H;C',K@#*,F:%E=ME&+:%#(_(ZQD8=`.
MRZ!"!LH[L@"7MH&&#-1KF6D0HS4TTB-(C[E<4K!9R3X9M+D(&8:650L(J@4-
M$75LY3'M`TX2^DZ3OBV7Q;QGBWU6RV6\7QF7+Y3+_0NFDL=T+5`Z8YOI_G*-
M'*`S;ANI(U]!&;47K9HF!H&P[*KLP_,@J-Z]P%$#IEA2FKM9Y,]36B-5`KT*
M(1XZX-SK/!ODCP1XZX)G@W_`O__:``@!`P,!/R&YF$0NT`(S4;2UJED+D-I,
MH'<U\G:*)U+MT>VPM!555F\0@-"TCL?#^_\`(TMVN^ZLS@R4XK5D8=B>1KIV
M5[%8U&M:_K)Y$^3/GR#^ZP.4(['HR``%<(Z4E%F$%W0,6Y_)CP"T)B4$_NC,
MJIIGZ+"I::Z:^[W5?+X<2C<$<G%[P7LDS(I*WP;*T*$TB5,5;TO,^]5I:PY@
M818-?NJ:/=_,/N9F9_':Z.@..UEU;FT*#S3JM^(:A_>?SK_-08>&LTS`>5#[
M94`\7%,]CRFX%.U3_&?_V@`,`P$``A$#$0``$,U9@);97F?]>;66:>`$L,>B
M/Z+;[;J/X(P!X">N*Z+5:5J*;V81VU@```LE@`HAMA*P0&@@"!AL%@!B!P`^
M`````````````/_:``@!`0,!/Q`;?&197K=`5^9;;:7JBEK"HH03YNK.:BU%
M(K1R9-K=O.J9;"CZS>&&/E;`,33;>$,RK,B(CSU[?)6O#H*QP=0J!:<?HW((
MV4$G6^24)Z&A^T3[-1',"T;^ZG'5]'.CL4+O=3=I&MRLL_N$"/\`K@Y0)C[(
M8(<RV1GZ^A^KH_LMF?<T/Y=#]EMSB)_-O@#1/YM\`8BJ@$8M_B=A/`HWMO@#
M??$8CAG/%K8^IH?RZ'[+9D*+XPH[W^`I@GU]#]71_9;,Q/K%)`K[LWJ)SOIG
MM5L)XJ:91X+&,L<@-QLNE2:W?<-O\)E"7OBW&F%@52BEEAQ^BU)`*U27/445
M2RI%*\')B[PTS=Y&$0Q^SAZ+[\.@Q5^7*P^EQ"'&##:=S,:)^A+XOD.\LZ6=
MM=4/2[OH>^7!6XN?^V,E:GSQX(F-MNH6O$2[%F]]=&-4V,6,GJ2P0^/5UTG-
MY:\]!#4HJJ*!`#%A:\UKS&\/N[(157U8&4XT>;9X7M+@QM']%PQ]-^**M^P!
MT?GKJFY\_3BW^H7\V["%,L,I`CN@Y,*'E=R_13TL*@=U:^C)].?$`_F]GL;E
M1O\`Z3F/H#PX($@<"7,[M9_HG1F0Q0>)PSB<4(N-*L/O<^_EC](OYMVG/XI=
M_P#]`:IZZ;0R1155KJKZO#*<Z/-L_I.O\45\L6*XSGN[EQ1)W*5@-2_`..\7
MNT>>VCD:-W'>=-[%)#2S0CV?/#'"FWT&Q12@HUW@KE=5I:15O&[F$@2>_6+3
M)!)]TI`A:,"`'O833@8*9++7N8UH67^.6RTA.^1?DO,5T1FRV^0Y[J+02^K/
ME-@O'J[UW77!+[(WW(K2UW\@6?M1[Y4)^;=I/ZUL.-;J6D<=C_\`Y0\_O$9?
MYN/S)@Z5FHF<%"L"UX`?!PPC`GW-[]R0^ESB8<7?2=/:0;<./#AA&!/ZM_78
MJU<]1(%T8,=[_`4P6%?"VJ+X1_I0;@HUX6O`#XH5@6O`#Y4#WDQO\`9`/#A?
M#<F>YQ*DON(/9W*IVP3ECW6C\?'71<'^>!TT]R=?&N"0-BQ<U6GV&N)8<C/!
M"HH;L$@EGRKR`AMX%Q@@$'OG'F)Q>AB$;1H?PJ!S`3&,D%9Q&'?O03?/Y]'Z
M7*/)N,52D;RD]._UE[:3!0<,(P)X5'OKZ2^[[@!VLOEY\.NUQ>E1^OJF^F75
M7H[L6I.5%OH)3GO^)3*\"XQ9-1LI80%"PX?5SZ`50]!C\@G#P@$@=4!;'5BW
MVX)83;[3YLX<;HSA7Q86?T_=_P#_V@`(`0(#`3\0M+=13U#^U-O8H0>C0$91
M<,2!"`SBV#*5;C0.M2B#0;A:$97YJ$1*1,(CD1PCKFQ]HUPQ#DE(@KJ-&I1B
M4U*]D^DH;J4M5#3B$;N`6GTGUGTE>R;%5"5C=P`9F>,1-GB>'H]W9:[.,T)2
M44B.*NK)76,USA0AEP"BZ7(6"ZFFQL$1\(B73FD&S@C<3)%&ECIJ>_<5OM%H
MN"RS?-=)VB'+`:0VB5N)"X;/GFG9\QXKF:.RS0E<P+@R)*4A&(.09"Y<G:4I
MR)8@9%-(-I66D'IES,`.+XJ!*U^4MQPU<.XJ[@NL[CN.GFZGFND[3>=H;15N
M7AL^>:54^\%(,;8N:A+HD4&(*0R,6C,K*-!6K8(L$`1,'&]J,11<EBZAS[^@
MJLU`D%I%D3@::L5?"`48ND5BLW(F#"`(#@29QTA`\(.UD4+:1(7UQ*97?7(N
MC-9)9B#62*NX*:BKO<%-0LQODL[BG#!K)%6]01J7F;[OB^$S0L='`2+*@YEZ
M&SP6NMY024(S$$UT/5I-X0+(MB0U0!W#V119)6H\H;"`::J6Y`JFPR;`*Y8.
M5V3&G<3VK-^#?YY&[<I$WQ:FMSI>^-&MS?ZX-N*7F.#?([-[]`';*//[S__:
M``@!`P,!/Q!IJ91&+Z1@D0@BQ`QB.SD`$`$%O,-%1L@7`HF1I&2<"&5ZS@$`
MT@TB)2.1P_L']?/^MB`"QH.!L!*T!FBS#!`H$8*U%@*AB!!M8((>$!8`:`0_
M3(_I'+0"%`5HM:"_*H!VH&680_?7H0T?W:7.4$3ZI"BJK?@UOZEH7\D1A'F_
MT"R,S9H$*-M#1BVA0R`A88J]"P-TLK8C>-96,`L$]N'+FH,!OI@Z5(H1@EY9
M<9+:P-_X$`Z"%$"NN*_:URE=NA=-)8[`6D!>$AS4.VZ#Y=`M9M0Q6D]]\BGI
J%&AHF4C%:K:"QK0AOPBV6MQ?)7<[3.@$76T;;B+]VB"(Q?O3(]_Q7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sig_jriley.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sig_jriley.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```"]0``"*@```HM```+=/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`*@!Y`P$1
M``(1`0,1`?_$`+X``0`#``,!```````````````'"`D$!0H&`0$`````````
M````````````$``"`@$#!`(#```````````%!@0'`Q`!"``@,`)@-18V%Q$`
M`@("``4`!`H&"P```````P0"!0$&$1(3%`<`$!46,"%!(C(C,S4V-R`Q45,T
M96%"8V0E1<76%Y<X$@$```````````````````!@$P$``@$#!`$%````````
M```!`!$A$"`Q,$!@0?!187&!D?_:``P#`0`"$0,1```!W\,X31X```````J>
M4<-*B:0```<,SE-!CZ`Q#)D)<(3):.G.:7A.&2(`?!%5R'#4@`K>1Z72!F<#
M14[P`$2D6F%IZ?@``1P<HHV=J7+)!!`A2(U8````!T1Y?3*(&OIZ?P?_V@`(
M`0$``04"ZN)\9:I;?.?>*3:0R)<*[6K5!LFNRDSP2)$>)'B\HT3)A%EA9R#U
MOQU-([%F,T<O8\J%QWL<;7ZDK@6`]QBJ6?'!,5[L0I*PLN&Y"IS$-S8BA3T/
MZM0N0<6*-8A376AL9BX]LVI^GZN9\8+CS3RR8TKI]JU("R+&8?9ICC847/V;
MHRM^7WE)#Q*A_FG,GOW3E'V-LRR$<0>X"ZJNZ$<CU';W!MJJSZM%HUVE]9\[
MA>[CXBGUEO?IVG&G7__:``@!`@`!!0+Y!__:``@!`P`!!0+Y!__:``@!`@(&
M/P)!_]H`"`$#`@8_`D'_V@`(`0$!!C\"]-.V[BQ9^/K]E+6-FJ0Y!AE"P4'L
M3%>S6]XY(4B6XKB9CX&N&4\TH!S:C`G+GX>PU_8-Z\<6E/:KY6>19W#7^F4?
M'$X2C.%G`H&`%A$@BCE$H2QC.$HSCC.(>*KS?Z7;],FJ%C1M]#;HO^Q42E8`
M#5=QL%)Y0&9#MN4;&)8A`61RG@8R8@NO7UF^Z78V#9,!411VFC;<:-+Z(EUE
MWB&,27R8CC.?@3MMG"JJJ$C#++!(!777##)#'.8F8C$$0XYE*4LXQ'&/1.TL
MM<\BT.K/-,IK[M:ZIU-3(ROAS'2#95%A:E;F8Z!!1P`1<\^,\W+&,Y1!:4ME
M7W%8UU.VL:MQ>P18Z)B+FZ#:A"KEZ3`I0ERRSRSCG&?CQZG-F0U73_."A'K&
MT(ONUI;5N\.&MR'6RD0U@X_X^M^PB:+AG7E('8+DW)`<\`X2QY)\*5OC9@4Z
MQ29[OQC46^N.6E@C)V:=+M6K55U3V,58#EQE.2\^&,_5XE`L1VVMT"/C)I@Z
M69%:T7W3AL%5#J#Z-BJW20(RID#/)\<\9"3[,D9PE*$H^*?)/C317[T:C+>G
M[L#1*+V?O5"AB/6(WG%<7"&QU8I1PV*<L\>.)<TN893W#%-K4->V)P;QZNYK
M[/8H#I;@^"$3L4J@-ZG6C@@Y*)!KPB(,<1Q'&(Q]*O5/=&&A7Z`BU^W[W?X4
MOJM?$:X>:YW4$!74Y;);.9/$A9E(1)8HY#)DLLYQ#94`;IM^TT=+KZ(MQ+LI
M@8JO>MX:YJU'6:FOUBIIZ?*-7'KM=N:76PV/FXRA+.54A)NV]F[GF#5U?9Y;
MPI$@QM6)Y6#E>DL@GU.,YD+'FSP@/$RRC"1*JPKJQ=%D)V*1U6^BR^V-+ML.
M^T*5NNK#)9A-N')E4MA#A]K(.<PQ/U['2J3"-JXH;BK6(Q*<5X,6%>PH&9Y#
M&4D0Q(7'-F,99X?)GTK]5?57A<:=5@T3<M5L(3,PI.J7G2P]IH/IJ3RG?()=
M7$9"D+YQ`<TYA)P'NM&<Z?A_:;:"N^ZHI6M/J:C;O+D%7[C0@4X1JJHC@@@=
M'CXL0E$8A&SE02WKL(7.A:P<MJQEM^P6JEJNY9:FUAPK,KRJBE<1.PQCB6<3
MXD7C+$^.)2QFNOZ34.RMJIF#B#?M_:&>@P/Z!.@W='6+P_9.$L>O=9VVW:U3
MV?O_`.0;"\4;8K%;XI1[+9\N(U2K;=S;X@M#$5Y8%UBPX8B/'Q8]*+<"Z<WK
MNG6MIGQY776P"N?:TQV;R+:FR.:F"G":LJ+:P1P@IEEP1,S9&>4.3YF3-"#Q
M;8YL%;,0K+<A28,UA7#+,RG@B$[,\B!&6`AYLXA&./T8;["KZ&V1KY59;91V
MQ2R[7RCR]M:I*-AKK>$,8AR]T(V89$+,>&1#Y?(9;V())2UBQ7#AE3+@_:[@
M^TUZ40Q"?,3POSK9$7A]07E)S1Y>;'WCO_\`VPC_`+R_3]YLZMKF=CY\%]X,
MT=9F[ZD085B3VKVW?<\5L=/CS\>3YOZO1_7=B0%95-D'I,KE^3^L,X"8X$7:
M7)C$QDAG$X3QC./3GU.W_P"8M1#QS[K[@Z-#>418P3/+5[9T^VM>)B\\^Z'Q
M@$<0KBX_'Z(([]2;;XJN'QI8`MNU!8I5SC+$^BUBNMHKYC*OKSYQ@C3@D1XC
M/$L\/G<K.-:V;7]ARET>\Q1W-=;=IW'5[?N>P98Z'7Z,^3FX<W+GA^K/K<CL
MVY4%6TA$$VJN3XF;P<6NET,QH4LLW1NI`\9_,!+ZO//]'&<^E$,5&_3^`J=X
M-RXY<!A6L>36*\:MG3?X+9JE<>U!YLP"#$1>*K*L2SF7#.`A!\%8_P`#_`M_
M>GW9]@3[Q_N/[W^SX^A?_*/W@C^4/XQ^E/[+^7_O_P"CAZZK\@/Q^C^/OS2_
MR+\%?Z=_,>IZ_P#_V@`(`0$#`3\AF#P&^UJ$*34["??R&J9A,9%AG_VS;`+@
MCASOZM^\L7794^G1=`3-5AE#%*@3$9\@EFO&M;`/U=PW<DMX*0):?6M?P`Q5
M((NJOY0?G5?:B(8*ZGBPBJ1F/@]U#C,@&:RH,DLP$0&>D(2P`D8:9^Z(`U];
MJNI7'\W93%T'W48IBIPGS:8X$1U*N!V63L#U.%24PT$3EI,0-GV!??;$!9(@
M2#-`?]C9ZUB\*E83A7F*U,/>">I_89YC[-0N$,]#&4Y'#+&#>J.TY`=49\QP
M]9*6IHIE;7\PQ,1'1-4A.0L=PY*@&(@*+Z&<JKYA&Z%UH8Q^Q'G4+10BF@#"
ML2"KA8B8772#6NIIO"(,2RUAN0RV5J;Q4BPK\R;!I?\`7KRKX`&-<HD]&P`1
M>R=FK/N#DS_\?Z?_V@`(`0(#`3\A\@__V@`(`0,#`3\A\@__V@`,`P$``A$#
M$0``$````````!(``````)`))(`!(```(```)```!)`!```````!`/_:``@!
M`0,!/Q"55^RB&[%&2*#++<?SX9!"X#*":EC?-SK8-KJHYVA@,L/\+HHI!;CO
M>X"F"!Q7X-6LT#WC:VRH09%@$$6]!_,O-6/;"1VJ>U7]&T[*%0,BQ:S$H/$L
MGYJ("[]'CM=KW_V_2EXR&WW"MR@>4<T1B%/WDC`HWO").Y@17!2]/1?K"TQ_
M'E+Q[!R,\`1@*&R+A@PS[(N\8%S'#!\$>/K$&1VZW1YP]`W?2)S[YRM,L\_1
M\K9=<@X"CI0<T!B&C@=0*_BLXE,"\&J/[-Y=L%5Z0OI,IW/<L;Q[K8L&$_0]
M+@4(&V2,XW%M8(22FRU:D0<B@IE&O"(H\@7XQX_J.HX%5<JB=GJ4C@<$U2]<
MABHO8`"*1*#[!$13C"Z12"O`@$7+'\_@_P#35?_:``@!`@,!/Q#R#__:``@!
)`P,!/Q#R#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
